Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Liparulo (Naples, Italy), R. Esposito (Naples, Italy), S. Mirra (Naples, Italy), G. Spaziano (Naples, Italy), A. Muñoz Ramírez (Santiago de Chile, Chile), A. Capuano (Naples, Italy), R. Filosa (Naples, Italy), C. Puglia (Catania, Italy), B. D'Agostino (Naples, Italy). RF22c, a 5-lipoxygenase inhibitor, in monocrotaline-induced PAH. 1421

Member's Comments

No comment yet.

Related content which might interest you: Treatment effects of Rho-kinase (Rock) inhibition vs. phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Effects of HIV protease inhibitors on monocrotaline-induced pulmonary hypertension in rats Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Roflumilast N-oxide, a PDE4 inhibitor, curbs bleomycin-induced lung fibroblast activation in vitro Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology Year: 2011 5-lipoxygenase inhibitor therapy in IPF Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008 Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001 The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 VIP prevents and reverses monocrotaline-induced PAH: Further protection by combination with bosentan Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Roflumilast N-oxide, a selective PDE4 inhibitor, curbs platelet-leukocyte interactions Source: Annual Congress 2011 - Translational models of disease Year: 2011 Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Hemodynamic and anti-remodelling effect of the Rho kinase inhibitor Y-27632 in the monocrotaline pulmonary arterial hypertension rat model Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Pharmacological inhibition of carbonic anhydrases 9 and 12 attenuates monocrotaline-induced pulmonary hypertension in rats Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice in vivo Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil Source: Eur Respir J 2010; 36: 800-807 Year: 2010 The hsp90 inhibitor, 17-AAG prevents and reverses the increases in lung calcineurin expression and activity associated with monocrotaline-induced right ventricular hypertrophy Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis? Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012